• Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page

CV.

Quote

anonymous

Guest
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
 




anonymous said:
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
Click to expand...
Wait, what? If we aren’t still 70/30, nobody told me.
 




anonymous said:
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
Click to expand...
Couple things, first, Entresto reps are not “floating by”, especially those of us that have sold it for a while. Maybe you are new but it hasn’t always been an easy sell. The cost alone is still an issue 8 yrs in. Some of us built this business to where it is now and it certainly wasn’t by floating by. Leqvio is incredibly easy to sell in comparison to Entresto, especially to primary. Second, the CV1 reps don’t OWN the Leqvio business, CV2 reps have been out here selling it too. And third, this is what Novartis and every other pharma company does. Don’t get comfortable thinking things will stay status quo.
 




anonymous said:
Couple things, first, Entresto reps are not “floating by”, especially those of us that have sold it for a while. Maybe you are new but it hasn’t always been an easy sell. The cost alone is still an issue 8 yrs in. Some of us built this business to where it is now and it certainly wasn’t by floating by. Leqvio is incredibly easy to sell in comparison to Entresto, especially to primary. Second, the CV1 reps don’t OWN the Leqvio business, CV2 reps have been out here selling it too. And third, this is what Novartis and every other pharma company does. Don’t get comfortable thinking things will stay status quo.
Click to expand...
I’ve been here for a long time, long enough to know that Entresto was difficult to launch, but yes at this point in the game it’s a float.
 




anonymous said:
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
Click to expand...
"Reps will be stepping all over each other for access to the same accounts . . ."
Not for long.
Seems you might have missed the point of what they are doing.
 








You forgot that the CV2's Entresto sales have been paying for your salary, benefits, car, etc.
Because Leqvio dismal sales are not paying for your job, pal.

And you forgot that CV1's having Entresto samples this entire time gave them access to providers and staff to talk about Leqvio. Good luck doing so without Entresto samples in the near future. Your value to the offices will dwindle quickly.



anonymous said:
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
Click to expand...
 








anonymous said:
Is there an update im not aware of? What will the CV2 payout be in Jan? Are Entresto samples going away?
Click to expand...
Agree, I haven’t heard a peep. Some managers pass things on to their team, but our team is usually the last to know everything. Will there be some announcement on the call today? Tell what you know.
 












anonymous said:
Can someone explain what is the point of having 100% Leqvio reps, who have had to battle all of the hurdles, and not get paid bonus for years and bust their butts to get this drug going, while entresto reps just floated by, received a bonus, and dropped samples. Then Novartis suddenly will flip the script and entresto reps will be more focused on Leqvio, how is that supposed to work? Reps will be stepping all over each other for access to the same accounts, and upset the offices in our small territories.
Click to expand...
You must be new. This is how they do it here. We’re all bumping into each other in every account. Least used drug but the most reps. It’s Novartis math.
 




As long as PH is not anonymous, no one will ask the tough questions that need to be asked at this CE Town Hall.
Will they keep 2 reps/territory in CV during the gap of 2025? My guess is no, probably not.
 




Top Bottom
Back
Quote